Milestone Pharmaceuticals (MIST) EBIAT: 2021-2022
Historic EBIAT for Milestone Pharmaceuticals (MIST) over the last 1 years, with Sep 2022 value amounting to -$14.6 million.
- Milestone Pharmaceuticals' EBIAT fell 2.33% to -$14.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$58.2 million, marking a year-over-year change of. This contributed to the annual value of -$42.9 million for FY2021, which is 14.24% up from last year.
- Per Milestone Pharmaceuticals' latest filing, its EBIAT stood at -$14.6 million for Q3 2022, which was up 13.79% from -$16.9 million recorded in Q4 2021.
- Milestone Pharmaceuticals' EBIAT's 5-year high stood at -$12.5 million during Q2 2021, with a 5-year trough of -$16.9 million in Q4 2021.
- In the last 2 years, Milestone Pharmaceuticals' EBIAT had a median value of -$14.4 million in 2021 and averaged -$14.5 million.
- Data for Milestone Pharmaceuticals' EBIAT shows a maximum YoY declined of 2.33% (in 2022) over the last 5 years.
- Quarterly analysis of 2 years shows Milestone Pharmaceuticals' EBIAT stood at -$16.9 million in 2021, then declined by 2.33% to -$14.6 million in 2022.
- Its EBIAT stands at -$14.6 million for Q3 2022, versus -$16.9 million for Q4 2021 and -$14.2 million for Q3 2021.